Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB® and COMVAX®
Merck & Co., Inc. announced that the Company has initiated a voluntary recall of 11 lots of its Haemophilus influenzae type B vaccine, PEDVAXHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)], and two lots of its combination Haemophilus influenzae type B/ hepatitis B vaccine, COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate)]. The recall is specific to these 13 lots and does not affect any other vaccines manufactured by Merck. The affected doses of PEDVAXHIB and COMVAX were distributed starting in April 2007. Merck is conducting this recall because it cannot assure sterility of these specific vaccine lots. Additional information is available at
http://www.merck.com/newsroom/press_releases/product/2007_1212.html.
